130 related articles for article (PubMed ID: 12871367)
21. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
[TBL] [Abstract][Full Text] [Related]
22. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor.
Lee AY; Vlasuk GP
J Intern Med; 2003 Oct; 254(4):313-21. PubMed ID: 12974870
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
Zhang B; Wieslander JB
Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
[TBL] [Abstract][Full Text] [Related]
24. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
25. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations.
Walenga JM; Pifarre R; Hoppensteadt DA; Fareed J
Semin Thromb Hemost; 1989 Jul; 15(3):316-33. PubMed ID: 2688104
[No Abstract] [Full Text] [Related]
26. Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries.
Gertz SD; Fallon JT; Gallo R; Taubman MB; Banai S; Barry WL; Gimple LW; Nemerson Y; Thiruvikraman S; Naidu SS; Chesebro JH; Fuster V; Sarembock IJ; Badimon JJ
Circulation; 1998 Aug; 98(6):580-7. PubMed ID: 9714116
[TBL] [Abstract][Full Text] [Related]
27. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis.
Kaiser B; Simon A; Markwardt F
Thromb Haemost; 1990 Feb; 63(1):44-7. PubMed ID: 2140204
[TBL] [Abstract][Full Text] [Related]
28. Induction of tissue factor in the arterial wall during recurrent thrombus formation.
D'Andrea D; Ravera M; Golino P; Rosica A; De Felice M; Ragni M; Cirillo P; Vigorito F; Corcione N; Tommasini P; Gargiulo A; Piro O; Calabró P; Chiariello M
Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1684-9. PubMed ID: 12869352
[TBL] [Abstract][Full Text] [Related]
29. Active-site inactivated FVIIa decreases thrombosis and necrosis in a random skin flap model of acute ischemia.
Alizadeh N; Pittet B; Tenorio X; Pyke C; Baetens D; Schlaudraff KU; Montandon D; Ezban M; Pepper MS
J Surg Res; 2004 Dec; 122(2):263-73. PubMed ID: 15555627
[TBL] [Abstract][Full Text] [Related]
30. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation.
Sørensen B; Johansen P; Christiansen K; Woelke M; Ingerslev J
J Thromb Haemost; 2003 Mar; 1(3):551-8. PubMed ID: 12871465
[TBL] [Abstract][Full Text] [Related]
31. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
[TBL] [Abstract][Full Text] [Related]
32. An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
Fareed J; Walenga JM; Iyer L; Hoppensteadt D; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):135-47. PubMed ID: 1772981
[TBL] [Abstract][Full Text] [Related]
33. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Wong PC; Crain EJ; Watson CA; Wexler RR; Lam PY; Quan ML; Knabb RM
J Thromb Thrombolysis; 2007 Aug; 24(1):43-51. PubMed ID: 17323133
[TBL] [Abstract][Full Text] [Related]
34. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.
Sarich TC; Osende JI; Eriksson UG; Fager GB; Eriksson-Lepkowska M; Ohlsson L; Carlsson S; Wåhlander K; Gustafsson D; Badimon JJ
J Thromb Haemost; 2003 May; 1(5):999-1004. PubMed ID: 12871368
[TBL] [Abstract][Full Text] [Related]
35. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models.
Bacher P; Walenga JM; Iqbal O; Bajusz S; Breddin K; Fareed J
Thromb Res; 1993 Aug; 71(4):251-63. PubMed ID: 8236155
[TBL] [Abstract][Full Text] [Related]
36. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
37. BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies.
Wong PC; Luettgen JM; Rendina AR; Kettner CA; Xin B; Knabb RM; Wexler R; Priestley ES
Thromb Haemost; 2010 Aug; 104(2):261-9. PubMed ID: 20589312
[TBL] [Abstract][Full Text] [Related]
38. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model.
Kirchhofer D; Tschopp TB; Baumgartner HR
Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1098-106. PubMed ID: 7627702
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site.
Jiao JA; Kelly AB; Marzec UM; Nieves E; Acevedo J; Burkhardt M; Edwards A; Zhu XY; Chavaillaz PA; Wong A; Wong JL; Egan JO; Taylor D; Rhode PR; Wong HC
Thromb Haemost; 2010 Jan; 103(1):224-33. PubMed ID: 20062929
[TBL] [Abstract][Full Text] [Related]
40. [Antithrombotic effects of recombinant hirudin in mice and its mechanism].
Cao WL; Li J
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2018 Apr; 34(4):371-374. PubMed ID: 30788948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
